Literature DB >> 33761606

In vivo bioavailability and in vitro toxicological evaluation of the new butyric acid releaser N-(1-carbamoyl-2-phenyl-ethyl) butyramide.

Roberto Russo1, Cristina Santarcangelo1, Nadia Badolati1, Eduardo Sommella2, Anna De Filippis1, Marco Dacrema1, Pietro Campiglia3, Mariano Stornaiuolo1, Maria Daglia4.   

Abstract

A large body of evidence suggests that supplementation of butyric acid exerts beneficial intestinal and extra-intestinal effects. Unfortunately, unpleasant sensorial properties and unfavourable physico-chemical properties strongly limit its use in food supplements and foods for medicinal purposes. N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA) is a new butyric acid releaser in solid form with neutral sensorial properties. The aim of this investigation is to provide preliminary information on its pharmacokinetic and toxicological properties through the study of a) in vivo bioavailability of FBA administered by oral gavage to male and female Swiss CD1 mice in comparison with sodium butyrate, b) the influence of digestion on FBA stability through an in vitro simulated oro-gastro-duodenal digestion process, and c) in vitro toxicological profile by means of the Ames Test and Micronucleus Test. The results reveal that FBA is a good butyric acid releaser, being able to increase butyrate serum concentration in a dose and time dependent manner in both male and female mice with a pharmacokinetic profile similar to that obtained from sodium butyrate as such. These data are confirmed by investigating the influence of digestion on FBA, which undergoes extensive hydrolysis following oro-gastro-duodenal digestion, especially in duodenal conditions, with a residual concentration of less than 10% of the initial FBA concentration. Finally, in the Ames and Micronucleus Tests, FBA does not show any in vitro genotoxicity as it is non mutagenic in the Ames Test and results to be unable to induce chromosome breaks in the Micronucleus Test. In conclusion, FBA is a new butyric acid releaser that can overcome the disadvantages of butyric acid while maintaining the same pharmacokinetic properties and safety profile, as shown by the results of the preliminary in vitro toxicological studies performed in this investigation.
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Butyric acid releaser; N-(1-carbamoyl-2-phenyl-ethyl) butyramide; in vitro toxicology; in vivo bioavailability

Mesh:

Substances:

Year:  2021        PMID: 33761606     DOI: 10.1016/j.biopha.2021.111385

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  2 in total

1.  Phenylalanine Butyramide Is a New Cosmetic Ingredient with Soothing and Anti-Reddening Potential.

Authors:  Ritamaria di Lorenzo; Antonietta Bernardi; Lucia Grumetto; Antonia Sacchi; Carmen Avagliano; Serena Coppola; Anna Fiorenza de Giovanni di Santa Severina; Cristina Bruno; Lorella Paparo; Sonia Laneri; Irene Dini
Journal:  Molecules       Date:  2021-10-31       Impact factor: 4.411

2.  A New Butyrate Releaser Exerts a Protective Action against SARS-CoV-2 Infection in Human Intestine.

Authors:  Lorella Paparo; Maria Antonia Maglio; Maddalena Cortese; Cristina Bruno; Mario Capasso; Erika Punzo; Veronica Ferrucci; Vito Alessandro Lasorsa; Maurizio Viscardi; Giovanna Fusco; Pellegrino Cerino; Alessia Romano; Riccardo Troncone; Massimo Zollo
Journal:  Molecules       Date:  2022-01-27       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.